Tumor necrosis factor-related apoptosis inducing ligand (TRAIL/Apo2L) can induce receptor-mediated apoptosis in prostate cancer cell lines that have been co-treated with the chemotherapeutic agent doxorubicin (Voelkel-Johnson C, et al. Cancer Gene Therapy 2002; 9:164-172). In this study, we report that pretreatment with doxorubicin is sufficient to sensitize cells to TRAIL. To identify possible targets of doxorubicin, we analyzed levels of several Bcl-2 family members, TRAIL receptors and the anti-apoptotic protein c-FLIP. Doxorubicin did not affect steady state levels of Bax, Bcl-2 and Bcl-X L in the majority of the prostate cancer cell lines. TRAIL receptor mRNAs (DR4, DR5, and DcR2) were induced by doxorubicin but these changes were not reflected at the protein level. In contrast, in response to doxorubicin, levels of c-FLIP, particularly FLIP S , decreased in all cell lines tested. The decrease in c-FLIP S correlated with onset and magnitude of caspase-8 and PARP cleavage in PC3 cells. In two TRAIL resistant cell lines, DU145 and LNCaP, treatment with TRAIL alone resulted in processing of c-FLIP L and initiated abortive caspase-8 proteolysis. TRAIL treatment did not affect levels of c-FLIP S in Du145 and LNCaP cells and did not result in PARP cleavage. Therefore, our results suggest that doxorubicin-mediated down regulation of c-FLIP S predisposes cells to TRAIL-induced apoptosis.
INTRODUCTION
Tumor necrosis factor related apoptosis inducing ligand (TRAIL/Apo2L) is a member of the TNF superfamily and like other death ligands can induce apoptosis by binding to corresponding death receptors. 1, 2 Four membrane bound TRAIL receptors have been identified. DR4/DR5 (TRAIL-R1 and -R2) contain intact cytoplasmic death domains and can transduce the apoptotic signal, whereas DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4) lack or have a truncated death domain and are presumed to be decoy receptors. [3] [4] [5] Upon ligand binding to DR4/5, the adaptor protein FADD and caspase-8 and/or caspase-10 are recruited to the cytoplasmic face of the receptor which results in the formation of the death inducing signaling complex (DISC) and initiation of the caspase cascade. 6, 7 The initiator caspases cleave and activate downstream effector caspases that are responsible for degradation of death substrates (i.e., poly(ADP-ribose)polymerase or PARP, a constituent of the DNA repair pathway) and the execution phase of apoptosis. In some cells, activation of effector caspases via death receptors occurs in a mitochondria-independent manner whereas in others, the apoptotic signal is amplified via a mitochondria-dependent pathway. Alterations in outer membrane integrity result in cytochrome c efflux from the intermembrane space, permitting association with Apaf I, caspase-9 and dATP to form the apoptosome, a caspase activating complex. Upon activation caspase-9 cleaves and activates downstream effector caspases.
The apoptotic pathway can be negatively regulated at the receptor level, with disruption of requisite DISC formation or altered DISC composition and at a number of points within the mitochondrial pathway. The caspase-8 homolog c-FLIP (FLICE inhibitory protein) can inhibit apoptosis at the DISC. 8 Multiple differentially spliced c-FLIP transcripts have been detected and two forms of the protein have been described, termed c-FLIP L (55kD) and c-FLIP S (26kD). Both proteins contain two death effector domains (DEDs) which permit association with the DEDs of adaptor proteins and/or caspase-8. c-FLIP L also contains a carboxy caspase-like domain with several amino acid substitutions, which result in a lack of catalytic function. Both the long and short forms of c-FLIP have been detected at the DISC where they act as dominant-negative inhibitors of caspase processing. In some but not all cells, high levels of c-FLIP expression correlate with a TRAIL resistant phenotype. 9, 10 Apoptosis is also regulated at points within the intrinsic (mitochondrial) pathway by pro-and anti-apoptotic proteins, which include members of the Bcl-2 family. 11, 12 This regulation occurs by the balance of intrinsic protein levels and/or their localization within intracellular compartments. Bax, a death agonist, facilitates cytochrome c release upon translocation to the mitochondrial membrane. Membrane permeablization by pro-apoptotic Bcl-2 family members is inhibited by death antagonists, such as Bcl-2 and Bcl-X L . Whether Bcl-2 or Bcl-X L protects cells from TRAIL-mediated apoptosis appears to be cell line dependent. For example, over expression of Bcl-2 or Bcl-X L inhibits or delays TRAIL-induced apoptosis in pancreatic and prostate cancer cell lines but not in cells of leukemic origin. [13] [14] [15] [16] We have previously shown that prostate cancer cell lines are relatively resistant to TRAIL but that cotreatment with the chemotherapeutic agent doxorubicin induces apoptosis via the mitochondria-dependent pathway. 17 The mechanism by which doxorubicin sensitizes cells to TRAIL is unclear. Numerous chemotherapeutic agents have been shown to enhance TRAIL cytotoxicity. The proposed mechanisms of sensitization include observed increase in TRAIL receptor expression via treatment with cisplatin, etoposide, taxol, and Ara-C [18] [19] [20] and elevation of the pro-apoptotic protein Bax by cisplatin. 21 Doxorubicin also increased DR5 levels in leukemic cells, but agonist receptor levels were not altered in studies using breast and colon lines. 22, 23 Thus these effects are likely cell line and dose dependent. Two studies have suggested that doxorubicin may magnify TRAIL-induced apoptosis at the mitochondrial level which implicated up regulation of apoptosome components. 24, 25 In the present study, we demonstrate that cotreatment of TRAIL and doxorubicin is not required for apoptosis. Rather, preincubation of prostate lines with doxorubicin was sufficient to induce TRAIL sensitivity. Levels of Bcl-2 family members Bcl-2, Bcl-X L or Bax were largely unaffected by doxorubicin. Agonist and antagonist receptor mRNA levels were strongly induced yet this was not reflected at the protein level. However, there was a clear decrease in c-FLIP S levels following doxorubicin treatment in all eight prostate cancer lines examined. Time course analyses in PC3 cells revealed a correlation between loss of c-FLIP S and onset of caspase-8 and PARP cleavage. Therefore, our results suggest that c-FLIP, in particular c-FLIP S , is a critical component of TRAIL resistance in prostate cancer cells. RNase Protection Assays. Cells were seeded at 2 x 10 6 /100mm plate, incubated overnight and treated with 1µg/ml doxorubicin for 8 hours. Total RNA was isolated using the RNAqueous kit (Ambion, Austin, TX). Probes were synthesized with the multiprobe template set hAPO-3d (BD Biosciences, PharMingen, Dan Diego, CA) using the T7 MAXIscript In vitro Transcription kit (Ambion) labelled with [α-32 P] UTP 800Ci/mmol 10mCi/ml (NEN, Perkin Elmer Lifesciences, Boston, MA) and the template DNA was removed with DNAFree (Ambion). 6 x 10 5 cpm were hybridized with 20µg total RNA and the RNase protection assay performed with the RPA III kit (Ambion). Both the transcription and RPA kits were used according to a modified protocol specified by Ambion for use with PharMingen multiprope sets with the following additional modifications: probes and markers were purified over Chromaspin-100 or Chromaspin-10 DEPC-H 2 O columns respectively (Clontech, Palo Alto, CA) following the DNase step (eliminating the extraction and precipitation steps) and the RNA and probes were coprecipitated as in the standard Ambion protocol. RPA products were separated on NOVEX QuickPoint denaturing acrylamide gels (Novex/Invitrogen, Carlsbad, CA). The gel was dried in an 80˚C oven for 10 minutes and the products visualized using a Phosporimager (Molecular Dynamics, Sunnyvale, CA).
MATERIALS AND METHODS

Cell
Antibodies and Western Blot Analysis. Cells were seeded at 2 x 10 6 /100 mm plate or 7 x 10 5 /60 mm plate, incubated overnight and subsequently treated with doxorubicin (1 µg/ml) and/or TRAIL (10 or 100 ng/ml) for the indicated times. Cells were rinsed with PBS and lysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS in PBS) containing a mammalian protease inhibitor cocktail (P-8340 Sigma, St. Louis, MO). Non-adherent cells were collected by centrifugation and combined with the adherent fraction unless otherwise indicated. Lysates were stored at -70˚C and were centrifuged (20,000 x g) prior to performing protein assays on the supernatant (DC protein assay, BioRad, Hercules, MA). Protein (50 µg) was separated on 4-12% Bis/Tris NuPage gels in MES buffer (Novex/Invitrogen) and transferred to nitrocellulose (Bio-Rad, Hercules, CA) for 60-90 minutes at 30V as recommended. Membranes were blocked in 5% milk in TBS-Tween for a minimum of 1 hour, and incubated with primary antibody in 0.5% milk (antiBax, Bcl-2, Bcl-X L , c-FLIP) or 5% milk (anti-DR4, DR5, DcR1, DcR2, Caspase-8, PARP, actin) in TBS-Tween, overnight at 4˚C or at room temperature (anti-FLIP primary). Dilution and source of antibodies were as follows: Bax and Bcl-X L (1:250, Transduction Laboratories, Lexington, KY), Bcl-2 (1:500, Transduction Laboratories), DR4 (1:1000, Alexis, San Diego, CA), DR5 (1:1000, Calbiochem, San Diego, CA), DcR1 (1:1000, Alexis), DcR2
(1:1000, Alexis), actin (1:2000, Sigma), c-FLIP (1:500 Dave-2, Alexis), Caspase-8 (1:2000, Alexis), PARP (1:5000, H-250, Santa Cruz Biotechnology Inc., Santa Cruz, CA). Following three washes with TBS-Tween, membranes were incubated with the appropriate HRP-conjugated secondary antibodies: anti-mouse (Sigma) at 1:3000-5000, anti-rabbit (1:50,000, Santa Cruz Biotechnology Inc., or Cell Signaling Technology, Beverly, MA), or anti-rat (1:15,000, Southern Biotechnology, Birmingham, AL). Membranes were washed three times in TBS-Tween followed by chemiluminescent detection of the secondary conjugates with DuraWest Supersignal (Pierce Biotechnology Inc., Rockford, IL). In some cases the blots were stripped with Re-blot Mild Solution (Chemicon, Temecula, CA) and reprobed. Erase-it (Pierce Biotechnology Inc., Rockford, IL) was used according to the manufacturer's instructions to obtain a clearer image of overexposed signals (caspase-8 preproform, Fig. 7 ).
RESULTS
Doxorubicin Pretreatment is Sufficient to Sensitize Cells to TRAIL.
We have previously shown that combination treatment with doxorubicin and TRAIL resulted in significant cell death in prostate cancer cells. 17 In the present study we asked if cotreatment of the cells with the two agents was required or if sequential treatment was also effective. A panel of eight prostate cancer cell lines was treated for 24 hours with doxorubicin alone, TRAIL alone, or both agents, as controls. In parallel, the same panel of cell lines was preincubated with doxorubicin alone or TRAIL alone for 8 hours. The first agent was removed and the cells were incubated an additional 16 hours with TRAIL alone or doxorubicin alone respectively, for a total experimental time of 24 hours. As seen in Figure 1 , TRAIL exposure followed by doxorubicin treatment was ineffective in inducing cell death and the cytotoxicity profiles essentially mirror that of doxorubicin or TRAIL alone. However, when the order of treatment was reversed, doxorubicin pretreatment was cytotoxic when followed by TRAIL at levels that approached that of the 24 hour cotreatment.
The Steady State Protein Levels of the Bcl-2 Family Members Bax, Bcl-2 and Bcl-X L are not Affected by Doxorubicin in the Majority of the Prostate Cancer Cell Lines. The mechanism by which doxorubicin sensitizes cells to TRAIL is unclear, although two studies have indicated that doxorubicin may amplify the mitochondrial pathway of apoptosis. 24, 25 Several members of the Bcl-2 family have also been implicated in the modulation of TRAIL mediated apoptosis. In bladder cancer cells TRAIL cytotoxicity was enhanced by cisplatin treatment which correlated with elevated levels of the proapoptotic protein Bax. 26 The DU145 cell line, which is more resistant to doxorubicin enhanced TRAIL apoptosis than the other lines used in this study, has been reported to contain a frameshift mutation in Bax with undetectable protein levels. 27 Transfection of wild type Bax rendered DU145 more sensitive to doxorubicin. 28 Ectopic over-expression of the anti-apoptotic mitochondrial protein, Bcl-2, in prostate cancer cell lines blocks TRAIL cytotoxicity 14 and doxorubicin has been demonstrated to reduce levels of Bcl-2 in bovine aortal endothelial cells. 29 Similarly, pancreatic cell lines transfected with Bcl-X L are resistant to both TRAIL and CD95L/FasL induced apoptosis. 13 We therefore asked if doxorubicin modulates the levels of these three proteins in the prostate cancer cell lines (Fig. 2) Figure 1 . Cytotoxic effect of sequential treatment. Cells were incubated with 10 ng/ml TRAIL, 1 µg/ml doxorubicin or both for 24 hours. Cells were also incubated with 10 ng/ml TRAIL for 8 hours followed by 1 µg/ml doxorubicin for 16 hours (TRAIL ➝ dox) or with 1 µg/ml doxorubicin for 8 hours followed by 10 ng/ml TRAIL for 16 hours (dox ➝ TRAIL). Cytotoxicity was measured by MTS assay. This is a representative experiment and similar results were obtained at least three times. In an attempt to determine what cellular alterations doxorubicin was inducing to affect TRAIL sensitivity, total RNA was isolated from the panel of eight prostate cancer cell lines following 8 hours of 1µg/ml doxorubicin incubation and assayed with a multi-probe set for expression of a battery of 12 apoptosis-related genes (Fig. 3) . There was a striking elevation of the mRNA for TRAIL receptors, DR5, DR4 and the decoy receptor DcR2 in most cell lines; DuPro expressed constitutively high levels of DR5 RNA. In addition, the mRNA of the adaptor protein TRADD was also markedly increased and TNFRp55 RNA levels decreased. TRADD is an adaptor molecule of the TNF-mediated pathway and its role, if any, in TRAIL-mediated apoptosis is unknown. The RPAs were repeated using three independent RNA preparations with similar results. The same pattern of induction was observed in LNCaP cells though an RPA was performed only once on RNA from these cells (data not shown). RNA was also isolated from the seven cells lines represented in Figure 2 following a 24 hour incubation with 10 ng/ml TRAIL. The RPA pattern of the TRAIL treated cells was similar to that of untreated cells (data not shown).
TRAIL receptor protein levels were determined using western blots (Fig. 4) . Notably, the steady state protein levels did not reflect the mRNA levels detected in the RPA. Though there was variation in DcR1 and DcR2 decoy receptor levels between the 8 lines there was no discernable change within each line following doxorubicin treatment. In contrast to the decoy receptors, differences in the protein levels of the two agonistic TRAIL receptors were observed in some cell lines. In general, DR4 receptor levels were static though there was an apparent increase in the CWR line at 8 hours and slight decrease in CWR, LNCaP and PC3 cells at 24 hours, despite the elevation of the DR4 RNA. In some of the lines there was an increase in the DR5 receptors, most notably CWR and DuPro, and in some experiments we also detected a slight increase in DR5 protein in PC3 cells. However, DR5 receptor levels in DU145, JCA1 and TsuPr1 were unaltered, yet these cell lines are sensitized to TRAIL by doxorubicin. In addition, DU145, which characteristically is most resistant to the combined treatment, expresses constitutively high levels of both DR4 and DR5. Similarly, the TRADD protein levels in each line were unchanged by doxorubicin despite the apparent increase in RNA (data not shown). There was a consistent lack of concordance between RNA and protein levels. Of particular note is the clear contrast between the increase in DR5 protein following c-FLIP Protein Levels Decrease in Prostate Lines in Response to Doxorubicin. c-FLIP levels have been shown to be sensitive to several agents, including metabolic inhibitors, which have been demonstrated to enhance the cytotoxic effects of membrane death receptor ligands. 9, 30, 31 c-FLIP levels have been reported to be unaffected by doxorubicin treatment in myeloma cells but ten fold less doxorubicin was used in that study. 24 Recently, c-FLIP S has been demonstrated to be an important mediator of TRAIL resistance. 32, 33 The same prostate cell lysates that were used in the western analyses in Figures 2 and 4 were probed with an anti-FLIP antibody that detects both the long and short forms of the protein (Fig. 5) . Doxorubicin treatment resulted in a decrease in c-FLIP S by 8 hours which was more marked at 24 hours in all lines. The levels of c-FLIP L also diminished in several of the lines, most notably PC3 and TsuPr1.
Temporal Profile and Requirement of Doxorubicin to Effect TRAIL Susceptibility and the Affect on c-FLIP, Caspase 8 and PARP Levels. To further investigate the effects of doxorubicin that may predispose cells to TRAIL induced apoptosis we performed time course experiments in PC3 cells, measuring viability (expressed as percent cytotoxicity), the levels of c-FLIP, and cleavage of caspase-8 and PARP.
Initially, the time of doxorubicin pretreatment required to enhance TRAIL cytotoxicity was determined. PC3 cells were cultured for 0 to 6 hours in the presence of 1µg/ml doxorubicin. This was followed by a 16 hour incubation with 10 ng/ml TRAIL. In parallel, PC3 cells were treated with both agents for a total of 24 hours. The shortest doxorubicin preincubation time, 1 hour, was sufficient to augment TRAIL cytotoxicity to 45%. A 6 hour doxorubicin pretreatment was as effective as the 24 hour cotreatment in inducing TRAIL-mediated cell death (Fig. 6 ).
Given these results we examined the protein levels and processed forms of FLIP, the initiator caspase-8, and PARP, a substrate of the effector caspases, in PC3 lysates. Cells were treated for 4 hours with doxorubicin, washed and incubated in media with or without TRAIL for an additional 2, 4, 6, or 20 hours for a total time of 6, 8, 10 or 24 hours. As shown in Figure 7 , levels of c-FLIP S declined within 4 hours of doxorubicin treatment alone and reached the lowest level at the 8 hour time point in both TRAIL treated and untreated cells. By 24 hours (20 hours after doxorubicin removal) levels of c-FLIP S began to recover. c-FLIP L levels did not decline as dramatically as c-FLIP S but the 55 kD protein was processed into a 43 kD form in TRAIL treated cells that represents the intermediate cleavage product. 8 Cleavage of preprocaspase-8 was evidenced by the appearance of an intermediate 43/41 kD form and the catalytically active p20/18 subunit. The p20/18 subunit was detected within two hours of TRAIL addition (six hour time point with long exposures). At the eight hour time point, 4 hours after doxorubicin removal and TRAIL addition, c-FLIP S reached minimal levels, which coincided with increased caspase-8 cleavage. A reduction in the p55 caspase-8 preproform was apparent at 24 hours. The timing and magnitude of PARP cleavage correlated with cleavage of caspase-8.
TRAIL Induces c-FLIP L Processing and Initial Cleavage of Preprocaspase-8. To segregate the effect of doxorubicin and TRAIL treatment on the observed processing of DISC components and PARP we examined levels of the same proteins in lysates from DU145, LNCaP and PC3 cells treated with 100 ng/ml TRAIL alone for 24 hrs. While 10 ng/ml TRAIL is not cytotoxic to any of the prostate cancer cell lines (defined as <10% cytotoxicity by MTS assay, Fig. 1 ) at 100 ng/ml TRAIL we observe 30-40% cytotoxicity in PC3 but not in LNCaP and DU145 cells. 17 In this experiment the media containing any debris or apoptotic cells were retained as separate samples and as expected only the PC3 media and wash had a visible pellet. c-FLIP S levels were unaltered with TRAIL treatment in DU145, LNCaP and adherent PC3 cells while c-FLIP S was not detected in the non-adherent fraction of PC3 cells (Fig. 8) . In all three lines the p43 processed fragment of c-FLIP L was detected with a loss of p55 in DU145 and LNCaP cells. This correlated with caspase-8 cleavage as evidenced by detection of the p43/41 fragment. Caspase-8 was further processed with release of the p20/18 large subunit only in the non-adherent PC3 fraction. PARP was also cleaved in this fraction. Thus in the combined treatment (Fig. 7) the decrease in c-FLIP S is mediated by doxorubicin and FLIP L cleavage is induced by TRAIL.
DISCUSSION
Neither TRAIL nor doxorubicin alone are effective cytotoxic agents in prostate cancer cell lines. As we previously reported, simultaneous treatment greatly magnifies the cytotoxic effect. 17 In this report we extend the previous study and demonstrate that this augmentation can be achieved by doxorubicin pretreatment but not by TRAIL incubation followed by doxorubicin treatment. In general, this sensitization did not influence the steady state protein levels of several Bcl-2 family members, regulators of the mitochondrial apoptotic pathway, though it remains possible that their subcellular compartmentalization was modified. The TRAIL agonist and decoy receptors were also not implicated as mediators of sensitization by doxorubicin. Though DR5 did increase in a subset of the lines this did not correlate with cytotoxicity; in the most resistant and sensitive lines, DR5 levels were unaltered. However the levels of the anti-apoptotic protein c-FLIP S were dramatically reduced in all cell lines examined. Cumulative data have clearly defined c-FLIP as a major regulator of death ligand response. FLIP S has been identified as an inhibitor of TRAIL mediated apoptosis in genetic screens. 32, 33 Selective molecular c-FLIP reduction using antisense oligonucleotides sensitized neuroblastoma, osteosarcoma and DU145 prostate cancer cells to CD95L/FasL. 30, 34, 35 Cisplatin down regulation of c-FLIP L correlated with CD95L/FasL sensitivity in osteosarcoma cells. 34 The apoptotic effects of the topoisomerase I inhibitor 9-nitrocamptothecin correlated with CD95 and CD95L synthesis and reduction of c-FLIP S (but not c-FLIP L ) protein levels in Du145 cells. 36 T lymphocytes are sensitive to CD95L/FasL when levels of c-FLIP are decreased and resistant when expression of cFLIP S increases, pointing to an important role of c-FLIP in immune homeostasis. [37] [38] [39] TRAIL receptor ligation induces DISC assembly with recruitment of FADD and caspase-8 as well as the FLIP isoforms. We observed that TRAIL treatment alone resulted in c-FLIP L processing to generate the p43 fragment and initiated abortive caspase-8 proteolysis as evidenced by detection of the p43/41 fragment. Only in lysates from cultures preincubated with doxorubicin (with concomitant loss of c-FLIP S ) did we observe the caspase-8 large catalytic subunit, p18, and downstream effector substrate (PARP) cleavage in response to TRAIL. Thus the loss of c-FLIP S predisposes cells to death ligand stimulated apoptosis wherein the caspase-8/c-FLIP ratio at the DISC determines productive caspase-8 association or abortive caspase-8 binding. An auto-and trans-proteolytic cleavage model of caspase-8 activation has recently been proposed based on the differential effect of c-FLIP L and c-FLIP S on preprocaspase-8 processing. 8 Both c-FLIP L and c-FLIP S stable transfectants were resistant to death receptor mediated apoptosis, blocked caspase-8 activation, and both were DISC components. 40 Different regulatory properties of the long and short alternatively spliced forms have also been postulated, due to observations that they may be differentially Figure 6 . Doxorubicin pretreatment required to obtain maximal sensitivity to TRAIL in PC3 cells. Cells were incubated for 0-6 hours with 1 µg/ml doxorubicin, washed twice and incubated for 16 hours with 10 ng/ml TRAIL. As a control cells were incubated with a combination of TRAIL and doxorubicin for 24 hours. Cytotoxicity was measured in the MTS assay. induced and that differentially processed fragments may bind different modifiers or components of the DISC. 40, 41 The nature of doxorubicin induced decrease of c-FLIP protein levels is unclear and several forms of regulation have been suggested. The rapid decrease in c-FLIP levels following treatment with metabolic inhibitors suggests that the protein is modulated at both the RNA and protein levels and regulation is likely cell line dependent. Both the MAPK and Akt signaling pathways have been implicated in c-FLIP regulation. 8 c-FLIP levels have also been demonstrated to be modulated by NF-κB signaling pathway. 41, 42 Activation of the transcription factor NF-κB positively regulates the levels of c-FLIP mRNA and protein, though different kinetics of long and short form induction were observed. 41 Treatment with proteasome inhibitors prevents p53 regulated FLIP degradation in lung and colon lines and suggest that turnover is via a ubiquitin-proteasome pathway. 43 The degradation of c-FLIP via ubiquination and proteasome pathway is also induced by PPARγ ligands in ovarian and prostate cancer lines, independent of NF-κB. 44 FLIP levels have been reported to vary during the cell cycle in T cells with elevated levels in G 1 and decreased levels in S phase 37 and this correlated with CD95L/FasL sensitivity. We have observed that doxorubicin treated PC3 cells accumulate in S-phase as determined by flow cytometry of propidium iodide stained cells (Kelly MM, unpublished observation).
It is certainly possible that modulation of c-FLIP levels is not the only effect of doxorubicin that may augment sensitivity to death ligands. Pleiotrophic effects of this drug include high affinity DNA binding, topoisomerase II inhibition and lipid association, which could modify the permeability and polarity of mitochondrial membranes. 45, 46 Mitochondrial membrane depolarization has been detected in myeloma cells treated with both TRAIL and adriamycin. 24 However, the results of this study indicate that doxorubicin pretreatment is sufficient to sensitize prostate cancer cells to apoptotic induction via TRAIL and that c-FLIP regulation is central to this response.
